Goldman Sachs
INMB icon

Goldman Sachs’s INmune Bio INMB Stock Holding History

Goldman Sachs’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Buy
231,586
+175,109
+310% +$250K ﹤0.01% 5960
2025
Q4 		$88.1K Buy
56,477
+41,173
+269% +$73.5K ﹤0.01% 6211
2025
Q3 		$31.7K Sell
15,304
-8,294
-35% -$19K ﹤0.01% 6210
2025
Q2 		$54.5K Sell
23,598
-17,118
-42% -$126K ﹤0.01% 5901
2025
Q1 		$318K Sell
40,716
-22,899
-36% -$182K ﹤0.01% 5423
2024
Q4 		$297K Buy
63,615
+30,606
+93% +$160K ﹤0.01% 5499
2024
Q3 		$178K Buy
33,009
+21,352
+183% +$152K ﹤0.01% 5491
2024
Q2 		$103K Sell
11,657
-75,948
-87% -$749K ﹤0.01% 5399
2024
Q1 		$1.03M Buy
+87,605
New +$1.06M ﹤0.01% 4328
2022
Q1 		– Sell
-20,053
Closed -$205K – 6721
2021
Q4 		$205K Buy
+20,053
New +$297K ﹤0.01% 5893

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Goldman Sachs's INMB Position: Q1 2026 in Review

Goldman Sachs increased its INmune Bio (INMB) stake by 310% in Q1 2026, buying an estimated $250K and bringing the position to 231,586 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #5960.

Goldman Sachs first reported a position in INMB in Q4 2021 and has held it in 10 quarters since. The position peaked at $1.03M in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Goldman Sachs held 231,586 shares of INmune Bio worth $262K as of Q1 2026.
  • Goldman Sachs bought 175,109 INmune Bio shares in Q1 2026, an estimated $250K.
  • INmune Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5960 holding.
  • Goldman Sachs first reported a position in INmune Bio in Q4 2021 and has held it in 10 quarters since.
  • Goldman Sachs's INmune Bio position peaked at $1.03M in Q1 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.